- Home
- Products
Reblozyl (Luspatercept–aamt)
Reblozyl (Luspatercept–aamt)
- Medicine Name: Reblozyl
- Generic Name: Luspatercept–aamt
- Strength: 25 mg / 75 mg
- Dosage Form: Lyophilized powder in single-dose vial for reconstitution
- Manufactured By: Celgene Corporation
Reblozyl is an erythroid maturation agent indicated for the treatment of:
- Anemia in adults with beta (β) thalassemia who require regular red blood cell (RBC) transfusions
- Anemia in adults with very low to intermediate-risk myelodysplastic syndromes (MDS-RS) or MDS/MPN-RS-T, who failed an erythropoiesis stimulating agent and need ≥2 RBC units over 8 weeks
Note: Reblozyl is not a substitute for urgent transfusion needs.
Recommended Dosage:
- Beta-thalassemia: 1 mg/kg subcutaneously every 3 weeks
- MDS-RS or MDS/MPN-RS-T: Dosage may vary; monitor hemoglobin and transfusion needs before each dose
- Discontinue if no benefit after 3 doses at maximum dose
- Minimum 3-week interval between doses
Thromboembolic Events (TEEs): Patients with beta thalassemia are at risk; monitor for signs of thrombosis and manage accordingly
Hypertension: Monitor blood pressure before each dose; manage with appropriate antihypertensives
Embryo-fetal Toxicity: May cause harm to a fetus. Use effective contraception during and for 3 months after the last dose
Hemoglobin Monitoring: Evaluate hemoglobin levels prior to each dose; if a transfusion occurred, consider pre-transfusion levels
Discontinue Immediately in case of serious adverse reactions or unacceptable toxicity
To import Reblozyl (Luspatercept-aamt) to India via GlobalRareMeds, the following documents are required:
- Valid prescription from a registered medical practitioner
- Patient’s diagnostic records supporting the medical need
- Government-issued identity proof of the patient
Order Confirmation:
Processed only after verification of the above documents and, where applicable, an import permit.
GlobalRareMeds sources Reblozyl 25 mg / 75 mg injections through authorized suppliers from the USA, Europe, Canada, and Australia, ensuring:
- 100% transparency and authenticity
- WHO-GDP compliant cold-chain handling
- Prompt fulfillment via our licensed facility in Ambernath, Thane District
We deliver across:
- India: Mumbai, Delhi, Chennai, Hyderabad, Ahmedabad, Bangalore, Kolkata, Pune, Jaipur, Lucknow, Chandigarh, and more
- Global locations where local laws permit import under named-patient supply
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name for Reblozyl?
A. The generic name is Luspatercept–aamt.
Q. Who manufactures Reblozyl?
A. Reblozyl is manufactured by Celgene Corporation.
Q. What conditions does Reblozyl treat?
A. It treats anemia associated with beta thalassemia and certain types of myelodysplastic syndromes (MDS-RS, MDS/MPN-RS-T).
Q. What is the dosage and form?
A. Reblozyl is available as 25 mg or 75 mg lyophilized powder for subcutaneous injection, every 3 weeks.
Q. Is Reblozyl approved by the FDA?
A. Yes, Reblozyl was approved by the FDA on November 8, 2019.
Q. What are the most common side effects?
A. Common side effects include:
Fatigue, headache, musculoskeletal pain, dizziness, diarrhea, nausea, cough, dyspnea, abdominal pain, and hypersensitivity.
Q. How should Reblozyl be stored?
A. Store refrigerated at 2°C to 8°C (36°F to 46°F) in its original carton, away from light. Do not freeze.
Q. Can I buy Reblozyl online in India?
A. Yes. If Reblozyl is not locally available, GlobalRareMeds can assist in legal procurement through the named-patient program.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
